TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks July 25, 2014
TCL Archive NCI Bioinformatics After Kenneth Buetow: Varmus Launches Fundamental Redesign January 6, 2012
